A Noninvasive Future: Prenatal Genetic Testing Looks to Single-Cell Methods as the Next Frontier

Albert, Helen

doi:10.1089/clinomi.04.04.16

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In most recent studies after an initial enrichment step, the enriched cell fraction is spread on a slide and automated microscopy coupled with laser capture microdissection or micropipette aspiration is used to obtain single fetal cell. The performance of the initial enrichment step is critical as high levels of fetal cell recovery/white blood cell (WBC) depletion would allow for better clinical scalability and therefore relevance . The reliance on laser capture microdissection to obtain the fetal cells adds significant complexity, cost, and scalability issues to such processes thus hindering the translation into clinics.…”

Section: Introductionmentioning

confidence: 99%

Isolation of Circulating Fetal Trophoblasts Using Inertial Microfluidics for Noninvasive Prenatal Testing

Winter

Hardy

Rezaei

et al. 2018

Adv Materials Technologies

View full text Add to dashboard Cite

While noninvasive prenatal testing based on cell‐free fetal DNA has recently revolutionized the field of aneuploidy screening in pregnancy, it remains limited to aneuploidy and microdeletion screening, and is unable to reliably detect single gene disorders. A number of recent studies have demonstrated the potential of circulating trophoblastic cells in providing cell‐based noninvasive diagnosis with sequencing or array‐based assays. However, considering the extreme rarity of these cells in blood, efficient, high‐throughput, and clinically applicable enrichment technologies are yet to be developed. This study demonstrates for the first time the utility of inertial microfluidics for efficient isolation of trophoblastic cells from maternal peripheral blood. Under optimal operating conditions, high‐recovery yields (79%) are obtained using a trophoblastic cell‐line, which is subsequently confirmed with analysis of maternal blood. Feasibility of obtaining a diagnosis from cells isolated from a maternal sample is demonstrated in a case of confirmed fetal trisomy 21 in which six fetal cells are found in a 7 mL blood sample using fluorescence in situ hybridization. Finally, it is demonstrated that trophoblastic cells isolated using inertial microfluidics could be picked and subjected to a clinically validated sequencing assay, paving the way for further validation of this technology and larger clinical studies.

show abstract

Section: Introductionmentioning

confidence: 99%